Member Info for beinthelead

He left because he was a blocker. Plain and simple. If it were up to him we’d go to DE242.

It’s a business. Get on with it! The BoD listened.

Also, more targeted drugs don’t exist. Even nonstandard of care drugs. It’s a bitter note from an ex Peel Hunt colleague.

Top man? Stood by his principles? Two massive assumptions. Assumptions you never like to make. Can we unpack the evidence you have to underpin said assumptions? Your negative bias is the underpinning.

The answer usually very simple. Neil Bell is a scientist that had a view. He previously contradicted AS saying P3 would be needed here.

IMO he left because this is a business, not a university. The recent structure changes are akin to making the business commercially aware. The SD had Eliot F dominating AS for the first time.

I believe there has been numerous calls to tell AS to ‘grt on with it’. It’s that simple. Keeping NB in post, and AS for that matter needed to change.

Nothing sinister, just business.

All valuations are subjective by nature. Listen to some on here. They’re mental.

Discount the top and the bottom. The truth is somewhere in between.

Https://twitter.com/lovinglife16764/status/1720021484179984709?s=46

Fake? It wasn’t. They have a note.

It literally doesn’t matter.

Your bones aren’t required. AS has said it comes this Q more times than eggy has posted about arthritis. There’s no conspiracy theory. No anterior motives. They’re releasing the data they have.

The SP has dropped this morning as no RNS on a Thursday. Yes, this share can now be traded based on a day of the week. Cannot wait for this to end…

Nice to see him deleted swiftly. What a lemon.

And that’s the point PL. Alan can say what he likes, but it’s these paid for brokers that drive the SP.

Data, along with case studies will move the needle. External validation by a customer is what deliver the re rate. Dare I say, inflection point 🥶

And here’s where it all falls down. A full days worth of posts on a topic you want your audience to engage with, progressively, yet you deny you own the Egbert handle on Twitter. Cool.

I’m all for a challenge. Especially with ASs previous history re ‘boosting’. All genuine posters have previously had their say. But these very weird angles, that are essentially questions you’ve made up, not risks , should be ignored. I think they are in the main.

No probs Wonga.

I believe the simple answer is normally the most valid. They simply don’t need to hide anymore. Chuck it out - it works.

The same person maybe??!

Because the data fully validates the platform. And they can. They always could. That line at the AGM about making a splash etc was massively conservative and overly protective.

I said earlier. That efficacy signal changed the game. No more chicken to play.

They won’t extrapolate the data for C7, leave the strange outlandish response extrapolations to Ophidian. That graph was beyond parody.

The data will be bounded by C6 and the RNS will contain the live data (narrative) from C7. I.e. C7 confirms that outcomes are improved in a dose dependant manner.

That efficacy signal changed everything. Everything.

Haha - yes. Autocorrect is a twit.

Alleged meeting?? Is this still being disputed??

Simply email AS and ask him to confirm if he attended. He’ll reply.

I don’t care very much for the TG, but hats to them for hating those notes.

The ‘data room’ thing is slightly exaggerated. Let the data arrive, then the deals.

The data baselines the platform validation and unequivocally exposes the tech’s potential.

Thorn - this has been asked of you quite a few times. Tether than risk, risks asking for others to do the research, list the assessment against each of the those risks in your last post.

Have you got any idea eggy?

Exactly moneysponge. However, its presence alerts people to sell. Which adds more pressure. If you want to trade this, it’s got a perfect calendar.